antifibrinolytic


Also found in: Encyclopedia, Wikipedia.

antifibrinolytic

 [an″te-, an″ti-fi″brĭ-no-lit´ik]
1. inhibiting fibrinolysis.
2. a substance that prevents fibrinolysis.

an·ti·fi·bri·no·lyt·ic

(an'tē-fī-brin'ō-lit'ik),
Denoting a substance that decreases the breakdown of fibrin (for example, aminocaproate.

antifibrinolytic

/an·ti·fi·bri·no·lyt·ic/ (-fi″brĭ-no-lit´ik) inhibiting or preventing fibrinolysis, or an agent that does this.

an·ti·fi·bri·no·lyt·ic

(an'tē-fī-brin-ō-lit'ik)
Denoting a substance that decreases the breakdown of fibrin (e.g., aminocaproic acid).

antifibrinolytic

inhibiting fibrinolysis.
References in periodicals archive ?
Treatment includes factor XI replacement (fresh frozen plasma, factor XI concentrate) or antifibrinolytic agents.
3] Treatment mainly includes local therapy, antifibrinolytics, and platelet transfusion.
The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial.
8) Tranexamic acid is an antifibrinolytic agent and is effective against blood loss in patients with increased fibrinolysis activity after surgery and in patients with a normal hemostatic pathway.
Currently available antifibrinolytic agents in the United States include tranexamic and aminocaproic acid solutions, however their use in dentistry has been controversial and are considered off-label.
Aminocaproic acid (Amicar) is an antifibrinolytic agent used for the treatment of excessive bleeding (3).
Antifibrinolytic agents for reducing blood loss in scoliosis surgery in children (review).
Preoperative, perioperative, and postoperative factor VIII and antifibrinolytic medication (tranexamic acid) protocols were given by the hematology specialist.
Panzica, "Four cases of cardiopulmonary thromboembolism during liver transplantation without the use of antifibrinolytic drugs," Anesthesia and Analgesia, vol.
Although haemorrhage is a well described major complication associated with this surgery, the preemptive use of antifibrinolytic agents was not attempted because of the concern about a possible increase in the risk of thromboembolic complications, such as deep vein thrombosis and acute myocardial infarction, related to the use of these drugs in human medicine [24, 25].
Gastrointestinal (GI) bleeding is a severe complication following hematopoietic stem cell transplantation (HSCT) in patients with thrombocytopenia, while hemostatic measures based on antifibrinolytic or transfusion therapy may not always be successful.